Literature DB >> 20431568

Personalized medicine in oncology: the future is now.

Richard L Schilsky1.   

Abstract

Cancer chemotherapy is in evolution from non-specific cytotoxic drugs that damage both tumour and normal cells to more specific agents and immunotherapy approaches. Targeted agents are directed at unique molecular features of cancer cells, and immunotherapeutics modulate the tumour immune response; both approaches aim to produce greater effectiveness with less toxicity. The development and use of such agents in biomarker-defined populations enables a more personalized approach to cancer treatment than previously possible and has the potential to reduce the cost of cancer care.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20431568     DOI： 10.1038/nrd3181

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  34 in total

1.  A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

Authors:  Anil Potti; Sayan Mukherjee; Rebecca Petersen; Holly K Dressman; Andrea Bild; Jason Koontz; Robert Kratzke; Mark A Watson; Michael Kelley; Geoffrey S Ginsburg; Mike West; David H Harpole; Joseph R Nevins
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

2.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

Authors:  Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria
Journal:  N Engl J Med       Date:  2006-09-07       Impact factor: 91.245

3.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

4.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Authors:  Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

5.  Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.

Authors:  Federico Innocenti; Deanna L Kroetz; Erin Schuetz; M Eileen Dolan; Jacqueline Ramírez; Mary Relling; Peixian Chen; Soma Das; Gary L Rosner; Mark J Ratain
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

Review 6.  Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.

Authors:  Vincent O Dezentjé; Henk-Jan Guchelaar; Johan W R Nortier; Cornelis J H van de Velde; Hans Gelderblom
Journal:  Clin Cancer Res       Date:  2009-01-01       Impact factor: 12.531

7.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

8.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

9.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.

Authors:  F Di Fiore; F Blanchard; F Charbonnier; F Le Pessot; A Lamy; M P Galais; L Bastit; A Killian; R Sesboüé; J J Tuech; A M Queuniet; B Paillot; J C Sabourin; F Michot; P Michel; T Frebourg
Journal:  Br J Cancer       Date:  2007-03-20       Impact factor: 7.640

Review 10.  American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Authors:  Carmen J Allegra; J Milburn Jessup; Mark R Somerfield; Stanley R Hamilton; Elizabeth H Hammond; Daniel F Hayes; Pamela K McAllister; Roscoe F Morton; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544
View more
  103 in total

Review 1.  Role of MetMAb (OA-5D5) in c-MET active lung malignancies.

Authors:  Mosmi Surati; Premal Patel; Amy Peterson; Ravi Salgia
Journal:  Expert Opin Biol Ther       Date:  2011-12       Impact factor: 4.388

Review 2.  [Is "evidence-based medicine" followed by "confidence-based medicine"?].

Authors:  Franz Porzsolt; Heiner Fangerau
Journal:  Med Klin (Munich)       Date:  2010-09-08

3.  Gene and drug matrix for personalized cancer therapy.

Authors:  Tim Harris
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

Review 4.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

5.  Noncovalent assembly of targeted carbon nanovectors enables synergistic drug and radiation cancer therapy in vivo.

Authors:  Daisuke Sano; Jacob M Berlin; Tam T Pham; Daniela C Marcano; David R Valdecanas; Ge Zhou; Luka Milas; Jeffrey N Myers; James M Tour
Journal:  ACS Nano       Date:  2012-02-16       Impact factor: 15.881

6.  An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.

Authors:  Oliver Jonas; Heather M Landry; Jason E Fuller; John T Santini; Jose Baselga; Robert I Tepper; Michael J Cima; Robert Langer
Journal:  Sci Transl Med       Date:  2015-04-22       Impact factor: 17.956

Review 7.  The challenges associated with molecular targeted therapies for glioblastoma.

Authors:  Toni Rose Jue; Kerrie L McDonald
Journal:  J Neurooncol       Date:  2016-02-22       Impact factor: 4.130

8.  Perspective: Flicking with flow: Can microfluidics revolutionize the cancer research?

Authors:  Tamal Das; Suman Chakraborty
Journal:  Biomicrofluidics       Date:  2013-01-31       Impact factor: 2.800

Review 9.  Does your gene need a background check? How genetic background impacts the analysis of mutations, genes, and evolution.

Authors:  Christopher H Chandler; Sudarshan Chari; Ian Dworkin
Journal:  Trends Genet       Date:  2013-02-28       Impact factor: 11.639

Review 10.  Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.

Authors:  Frank S Ong; Kingshuk Das; Jay Wang; Hana Vakil; Jane Z Kuo; Wendell-Lamar B Blackwell; Stephen W Lim; Mark O Goodarzi; Kenneth E Bernstein; Jerome I Rotter; Wayne W Grody
Journal:  Expert Rev Mol Diagn       Date:  2012-07       Impact factor: 5.225
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.